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AbstrAct
Chronic kidney disease (CKD) is higher in elderly, 
but mortality outweighs the risk of end-stage renal 
disease (ESRD). Our aim was to identify prognostic 
markers for ESRD or death in elderly CKD, within 
a competing-risk analysis. This is a longitudinal 
study of consecutive newly referred patients with 
CKD ages 65 years, followed until the time of the 
first event (ESRD or death), using a competing-risk 
analysis. A modified Charlson Comorbidity Index 
(mCCI) was subdivided into subgroups (0-2, 3-4, 
≥5). Patients were followed for hospitalizations 
that occurred prior to the outcomes. Among 416 
patients, age 76±8 years, 52% male, median 
estimated glomerular filtration rate of 32 mL/
min per 1.73 m2, 50% had diabetes, and 67% 
cardiovascular disease. Over a median follow-up of 
3.6 years, 36 patients progressed to ESRD (8.7%) 
and 103 died (24.8%). Older age (subdistribution 
HR (sHR)=1. 06; p<0.001), creatinine≥1.6 mg/
dL (sHR=2.03, p=0.004), hemoglobin <11 g/dL 
(sHR=1.91, p=0.003), mCCI score≥5 (sHR=3.01, 
p<0.001) and having one or more hospitalizations 
(sHR=1.73, p<0.001) were associated with death 
before ESRD. The independent predictors for 
ESRD with competing risk of death were: lower 
age (sHR=0.94; p=0.009), creatinine≥1.6 mg/
dL (sHR=3.26, p=0.006), hemoglobin <11 g/dL 
(sHR=2.15, p=0.027), peripheral vascular disease 
(sHR=3.45, p=0.001) and having one or more 
hospitalizations (sHR=1.56, p=0.031). Elderly 
referred patients with CKD are near threefold more 
likely to die than progress to ESRD. A competing-
risk framework based on available clinical and 
laboratory data may discriminate between those 
outcomes and could be used as a decision-making 
tool.
IntroductIon
The world’s population is aging, and by demo-
graphic projections, in 2050, about 32% of the 
Portuguese population is projected to be aged 
65 and over, meaningfully above the European 
Union average of 25.7%.1
Parallel to this, the prevalence of chronic 
kidney disease (CKD) is rising worldwide, and 
the elderly represent the most rapidly growing 
segment of the end-stage renal disease (ESRD) 
population requiring renal replacement therapy 
(RRT) in wealthier countries.2 3 Portugal has the 
highest unadjusted incidence and prevalence of 
ESRD among European countries4 and 67.7% 
of the incident dialysis patients, in 2015, were 
over 65 years with a mean age of prevalent 
patients of 66.7 years.5
Despite the growing number of older 
patients initiating dialysis, another problem 
stands out in this group: mortality, mainly 
from cardiovascular disease, outweighs the risk 
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significance of this study
What is already known about this subject?
 ► Prevalence of chronic kidney disease 
(CKD) is rising worldwide, and the elderly 
represent the most rapidly growing 
segment of the end-stage renal disease 
(ESRD) population requiring renal 
replacement therapy.
 ► Mortality, mainly from cardiovascular 
disease, outweighs the risk of progression 
to ESRD in older patients with CKD.
What are the new findings?
 ► Our study includes the rigorous exploration 
of the first Portuguese CKD cohort that 
included patients aged 65 years over, newly 
referred to nephrology.
 ► We demonstrated that peripheral vascular 
disease was an independent predictor 
for ESRD, but was not associated with 
increased pre-ESRD mortality.
 ► We implemented a competing risk 
framework for the statistical analysis to 
examine risk factors based on available 
clinical and laboratory data, for ESRD 
and differentiating them from those that 
increase mortality.
How might these results change the focus 
of research or clinical practice?
 ► Identifying predictors of death and ESRD 
within a competing-risk approach may 
allow us to use them as a decision-making 
tool, enabling more targeted therapeutic 
intervention, in elderly patients with CKD.
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of progression to ESRD.6 7 One of the major challenges to 
clinicians caring for older patients with CKD is to identify 
each patient’s risk for progressive CKD and likelihood for 
requiring RRT in relation to the competing risk of death. 
This may involve important clinical decisions, such as 
referrals and procedures for dialysis access placement or 
transplant decision or on the contrary the possibility to 
identify patients with higher comorbid conditions at high 
risk of early death for which conservative management 
may be the best option.
Our aim was to characterize elderly patients with CKD 
who were newly referred to our outpatient department to 
determine the independent predictors of ESRD or death 
through a competing-risk analysis. Furthermore, we sought 
to identify potential variables that may indicate a higher 
likelihood of death before ESRD or of attaining first ESRD 
status.
MetHods
study design and population
This longitudinal retrospective study included consec-
utive patients aged ≥65 years with CKD (non-dialyzed 
and non-transplanted), newly referred to our outpatient 
Nephrology department in Hospital de Santo António, 
CHUP, between January 1, 2012 and December 31, 2012, 
followed until the occurrence of the first event (ESRD 
or death) or until the end of the study (April 30, 2016). 
Hospital de Santo António is a tertiary-care hospital affili-
ated with the Abel Salazar Institute of Biomedical Sciences, 
University of Porto, which serves a diverse population of 
500,000 inhabitants in the North region of country.
The study was performed in accordance with the Decla-
ration of Helsinki and approved by the Institutional Review 
Board of CHP.
The diagnosis of CKD was done by the KDIGO 2012 
criteria.8 ESRD was defined as the need for RRT initiation 
or transplantation.
Baseline data included gender, age, weight, height, body 
mass index (BMI), CKD stage, proteinuria level, medi-
cation use, and associated comorbid conditions, such as 
diabetes, dyslipidemia, hypertension, smoking status, and 
cardiovascular disease (coronary artery disease, peripheral 
artery disease, and cerebrovascular accident). Coronary 
artery disease was defined as a previous myocardial infarc-
tion, angina pectoris, coronary artery bypass grafting, or 
coronary stent implantation. Peripheral artery disease was 
defined as the presence of intermittent claudication or with 
the need of peripheral revascularization or amputation.
Glomerular filtration rate (GFR) was estimated using 
the Chronic Kidney Disease Epidemiology (CKD-EPI) 
2009 creatinine equation.9 Etiological diagnosis of CKD 
was based on the patient’s history, proteinuria, kidney 
ultrasound, and kidney biopsy, when available. Data 
blood and urine routine measurements were collected: 
hemoglobin, platelet, serum albumin, urea nitrogen, 
creatinine, sodium, potassium, bicarbonate, chloride, 
calcium, phosphorus, intact parathyroid hormone (PTH), 
glucose, hemoglobin A1c, uric acid, lipid profile, iron, 
unsaturated iron binding capacity, ferritin, urinary sedi-
ment, and urine protein-to-creatinine ratio in spot urine 
sample.
Cognitive status was evaluated and screened using the 
Mini Mental State Examination,10 and classified as cogni-
tive impairment if the score was 23 or lower.
Functional dependency was defined as the requiring of 
assistance in the activities of daily living and classified as 
totally dependent, partially dependent, and autonomous.
A modified version of the Charlson Comorbidity Index 
(mCCI),11 12 that is, by excluding subject’s age and presence 
or absence of kidney disease, was calculated to assess severity 
of comorbidities and subdivided into three subgroups (0–2, 
3–4, and ≥5).
During the follow-up, number and reasons for hospi-
talizations were registered, all-cause hospitalization and 
cardiovascular-related hospitalization, defined as hospital-
ization secondary to cardiovascular events (coronary artery 
disease, congestive heart failure, stroke or transient isch-
emic attack, peripheral artery disease). The cause of death 
was categorized as cardiovascular (defined as death due to 
cardiac, cerebrovascular, atherosclerotic or other vascular 
causes), malignancy, infection, other, and unknown causes.
statistical analysis
Baseline characteristics for the all sample and by primary 
outcomes of interest are presented as medians with IQRs 
for continuous non-normally distributed variables and 
as proportions for categorical variables. Subgroups were 
compared using the χ2 for categorical and Mann-Whitney 
test for continuous variables.
Unadjusted incidence rates for progression of ESRD 
(defined as renal failure requiring RRT or transplant) and 
all-cause mortality before any RRT (pre-ESRD death) were 
calculated per 100 person-years.
Hospitalization rate was calculated as the number of 
hospital admissions, divided by years at risk, expressed as 
hospitalizations per patient-year, using Poisson regression.
Survival analysis was performed and the two outcomes of 
interest were progression of ESRD and all-cause mortality 
before any RRT (pre-ESRD death). These two events were 
considered as competing risks. Patients without any of these 
outcomes were censored at the date of their last recorded 
visit or at the end of the study period.
Regression models taking competing risks into account 
were carried out to analyze the independent effect of covari-
ates on each of two competing endpoints. This analysis was 
performed considering two types of hazards: cause-specific 
hazard and subdistribution hazard. Proportional cause-spe-
cific hazard regression models were performed using the 
standard Cox (cause-specific hazard regression model), 
censoring all patients without the event of interest. If a 
patient initiated dialysis, then the endpoint of mortality 
was censored. If a patient died, then the outcome of dialysis 
initiation was censored. An alternative model proposed by 
Fine and Gray13 was the approach used in the current study 
to model the subdistribution hazard.
An exploratory analysis was performed to examine 
the unadjusted effect of the potential predictors of ESRD 
progression and patient death by fitting univariable models. 
The cause-specific HR and the subdistribution HR for ESRD 
or for patient death before any RRT were then estimated in 
multivariable analyses. The covariates were selected on the 
basis of univariate analysis and because of their potential 
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biological plausibility to predict progression of ESRD and/
or death.
The variables included in the univariate competing-risk 
model were baseline age, gender, baseline serum creat-
inine (<1.6 or ≥1.6 mg/dL, the median value for this 
sample), serum hemoglobin (<11 or ≥11 g/dL),14 BMI 
(<18.5, 18.5–24.9, 25–29.9, or ≥30), estimated GFR 
(eGFR) (continuous or categorized as <60 or ≥60 mL/
min), tobacco use (never, former, or current), dyslipidemia, 
hypertension, diabetes, coronary artery disease, peripheral 
vascular disease, cerebrovascular disease, number of antihy-
pertensive drugs, referral from primary care versus another 
hospital appointment, CKD etiology (diabetes vs others), 
cognitive status, functional dependency, mCCI score at 
baseline, and the occurrence of hospitalizations during the 
follow-up period. For both outcomes, the occurrence of 
hospitalizations during the follow-up period was used as a 
time-varying covariate.
Statistical analyses were performed using SPSS V.22.0 
and STATA V.13.0 software packages. A significance level 
of 0.05 was considered.
results
baseline characteristics
Among 416 patients newly referred, 52% were male, with 
a mean age of 76 years, and 36% of them aged 80 years 
or more. Their baseline characteristics are summarized in 
table 1.
Fifty per cent of the patients were referred by primary 
care physicians. At baseline, they had a median eGFR of 
32 mL/min per 1.73 m2. The most frequent etiologies of 
renal disease were ischemic nephropathy (38%), diabetic 
nephropathy (25.5%) and unknown causes (13.5%).
Most of the patients were non-smokers (74%) and 22% 
were obese (BMI >30 kg/m2). About 50% were diabetic, and 
96% presented hypertension, of which 50% were receiving 
more than two antihypertensive drugs, renin–angiotensin 
blockade in 33% of them; 63% of the patients had a systolic 
blood pressure >130 mm Hg. Dyslipidemia was present in 
85% of the patients, 60% were under lipid-lowering medi-
cation. An active or previous malignancy was present in 
15% of the patients. Cardiovascular disease was present in 
67% of the patients, including coronary artery disease in 
25%, peripheral vascular disease in 19% and cerebrovas-
cular disease in 23% of the patients.
Regarding functional dependency, 5% of the patients 
were totally dependent and 38% were partially dependent. 
Cognitive impairment was present in 11% of the patients.
Most patients had a hemoglobin level ≥11 g/dL (71%), 
with no iron deficiency (ferritin level ≥100 ng/mL: 75%; 
transferrin saturation ≥20%: 62%).
Intact PTH was elevated in 81% of the patients, despite 
good control of calcium–phosphorus levels.
Follow-up and outcomes
During a median follow-up of 3.6 years (min–max: 0.02–
4.3 years), 36 patients progressed to ESRD (8.7%) and 103 
patients died (24.8%) prior to ESRD, giving an ESRD rate 
of 2.7/100 patient-years and a mortality rate of 7.8/100 
patient-years, respectively. Figure 1 shows the cumulative 
incidences of events, considering competing risks.
The leading causes of death prior to ESRD were cardio-
vascular (35%), infection (29%), malignancy (21%), other 
causes (8%), and unknown (7%).
Concerning the 36 patients who initiated RRT, all of 
them hemodialysis, 18 patients started treatment with an 
arteriovenous fistula and 18 patients with a venous cath-
eter. It should be mentioned that eight patients of overall 
cohort (1.9%) that underwent fistula died without receiving 
dialysis.
Hospitalizations
During the follow-up period, 222 patients (53%) were 
hospitalized for any reason, with a global hospitalization 
rate of 0.38 per patient-year. Stratifying for the competing 
events, the hospitalization rate was 1.27 per patient-year 
in the patients with ESRD, and 1.06 hospitalizations per 
patient-year in the patients who died before ESRD.
Cardiovascular-related hospitalization accounted for 
almost 40% of the hospitalization events during the same 
period. The global cardiovascular hospitalization rate was 
0.15 hospitalizations per patient-year, being 0.56 cardio-
vascular hospitalizations per patient-year in the patients 
with ESRD and 0.39 hospitalizations per patient-year in the 
patients who died before ESRD.
competing-risk analysis of death and esrd
The Cox proportional hazards model indicated that base-
line younger age, creatinine higher than 1.6 mg/dL, hemo-
globin lower than 11 g/dL, peripheral vascular disease 
diagnosis, and the occurrence of one or more hospitaliza-
tions (all-cause hospitalizations) during the follow-up were 
associated with higher risk of ESRD (table 2). Diabetes 
mellitus (vs other CKD etiologies) and mCCI score at base-
line were not associated with higher risk of ESRD.
Older age, creatinine higher than 1.6 mg/dL, hemoglobin 
lower than 11 g/dL, mCCI score ≥5, and the occurrence of 
hospitalizations during the follow-up were associated with 
death before ESRD.
Conversely, subhazard ratios estimated from compet-
ing-risk regression necessarily discriminated between 
endpoints. Significant risk factors for ESRD included 
younger age, creatinine higher than 1.6 mg/dL, hemo-
globin lower than 11 g/dL, peripheral vascular disease, and 
the occurrence of one or more hospitalizations during the 
follow-up (table 3).
Risk factors for pre-ESRD death included older age, 
creatinine higher than 1.6 mg/dL, hemoglobin lower than 
11 g/dL, mCCI score ≥5, and the occurrence of one or 
more hospitalizations during the follow-up. By adjusting 
for these competing risks, we show that peripheral vascular 
disease increases the cumulative incidence of ESRD, but is 
not associated with increased pre-ESRD mortality. Simi-
larly, a mCCI score ≥5 increased the hazard for pre-ESRD 
death, but not for RRT initiation.
dIscussIon
In our cohort, newly referred patients aged over 65 years 
with CKD were near threefold more likely to die than 
progress to ESRD. These results were consistent with those 
found in previous studies confirming that elderly CKD are 
group.bmj.com on April 3, 2018 - Published by http://jim.bmj.com/Downloaded from 
1044 Santos J, et al. J Investig Med 2017;65:1041–1048. doi:10.1136/jim-2017-000480
table 1 Baseline clinical characteristics of patients divided by outcomes
total, n=416
Alive without
esrd, n=277 esrd, n=36
dead without
esrd, n=103 p Value
Age (years) 71 (71–83) 76 (70–82) 74 (71–80) 81 (75–86) 0.017*
Age ≥80 years, n (%) 149 (36) 87 (31) 7 (19) 55 (53) <0.001*
Male, n (%) 218 (52) 139 (50) 21 (58) 58 (56) 0.430
eGFR EPI (mL/min/1.73 m2) 32 (23–42) 33 (25–44) 24 (16–38) 28 (22–34) <0.001*
CKD stage, n(%)
  Stage 1 6 (2.0) 4 (1.0) 0 (0.0) 2 (2.0)
  Stage 2 34 (8.0) 30 (11) 1 (3.0) 2 (2.0) 0.004*
  Stage 3a 46 (11) 45 (16) 1 (3.0) 0 (0.0)
  Stage 3b 139 (33) 101 (37) 7 (19) 31 (30)
  Stage 4 158 (38) 88 (32) 11 (31) 59 (57)
  Stage 5 34 (8.0) 9 (3.0) 16 (44) 9 (9.0)
Referral, n(%)
  Primary care 206 (50) 123 (44) 21 (58) 50 (49) 0.013*
  Hospital appointment 194 (47) 148 (53) 14 (39) 44 (43)
  Other 16 (3.8) 6 (2.2) 1 (2.8) 9 (8.7)
Primary renal disease, n (%)
  Ischemic nephropathy 158 (38) 105 (38) 13 (36) 40 (39)
  Diabetic nephropathy 106 (26) 63 (23) 15 (42) 28 (27) 0.222
  Glomerulonephritis 16 (3.8) 10 (3.6) 1 (2.8) 5 (4.9)
  Other/unknown 136 (33) 99 (36) 7 (19) 30 (29)
BMI (kg/m2) 27 (24–30) 27 (24–31) 26 (24–30) 26 (23–29) 0.112
Cognitive impairment, n (%) 47 (11.3) 30 (10.8) 3 (8.3) 14 (13.6) 0.632
  Totally dependent 24 (5.8) 15 (5.4) 2 (5.6) 7 (6.8)
  Partially dependent 156 (38) 96 (35) 17 (47) 43 (42) 0.430
  Autonomous 236 (57) 166 (60) 17 (47) 53 (52)
mCCI, n (%)
  0–2
  3–4
  >5
184 (44.2)
127 (30.5)
105 (25.2)
148 (53.4)
84 (30.3)
45 (16.2)
12 (33.3)
12 (33.3)
12 (33.3)
24 (23.3)
31 (30.1)
48 (46.6)
<0.001*
Diabetes, n (%) 207 (50) 133 (48) 52 (61) 49 (51) 0.330
Former/current  
smoking, n (%)
110 (27) 66 (24) 11 (31) 33 (32) 0.246
SBP (mm Hg) 140 (125–155) 141 (127–158) 138 (120–159) 132 (121–150) 0.037*
DBP (mm Hg) 70 (63–80) 71 (64–80) 77 (60–81) 68 (60–76) 0.017*
Antihypertensive ≥2, n (%) 207 (50) 140 (51) 18 (50) 49 (48) 0.876
Renin–angiotensin  
blockade
137 (33) 88 (32) 16 (44) 33 (32) 0.306
Diuretics 295 (71) 196 (71) 30 (83) 69 (67) 0.177
Dyslipidemia, n (%) 354 (85) 238 (86) 30 (83) 86 (84) 0.801
Lipid-lowering medication, 
n (%)
248 (60) 168 (61) 22 (61) 58 (56) 0.712
Antiplatelet medication, 
n (%)
203 (49) 135 (39) 14 (52) 54 (49) 0.376
Cardiovascular diseases, 
n (%)
277 (67) 172 (62) 22 (61) 65 (63) 0.739
Peripheral vascular disease, 
n (%)
78 (19) 43 (16) 15 (42) 20 (19) 0.001
Albumin <3.5 g/dL, n (%) 40 (11) 24 (10) 5 (15) 11 (12) 0.667
Uric acid (mg/dL) 7.3 (5.6–9.8) 7.2 (5.4–9.6) 7.4 (5.9–9.3) 7.7 (6.2–11.3) 0.367
Total cholesterol (mg/dL) 176 (147–205) 179 (150–205) 175 (142–207) 168 (142–204) 0.355
HDL (mg/dL) 47 (38–57) 48 (39–57) 48 (36–59) 45 (37–58) 0.720
LDL (mg/dL) 98 (75–123) 99 (79–121) 95 (71–118) 95 (74–132) 0.673
Hemoglobin (g/dL) 11.9 (10.6–13.6) 12.0 (10.9–13.4) 11.3 (10.6–13.1) 11.6 (10.1–13.1) 0.086
TSAT (%) 21(14–28) 21(15–28) 21(15–33) 21(14–28) 0.642
Ferritin (ng/mL) 160 (80–337) 150 (77–344) 151 (70–256) 181 (90–363) 0.407
Continued
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total, n=416
Alive without
esrd, n=277 esrd, n=36
dead without
esrd, n=103 p Value
iPTH (pg/mL) 100 (61–155) 98 (61–161) 115 (69–140) 99 (61–156) 0.446
Calcium (mg/dL) 2.4 (2.3–2.5) 2.4 (2.3–2.5) 2.4 (2.3–2.5) 2.3 (2.2–2.5) 0.158
Phosphate (mg/dL) 1.1 (0.99–1.25) 1.1 (0.99–1.24) 1.1 (0.90–1.17) 1.2 (1.00–1.33) 0.292
uPCr (g/g) 0.25 (0.1–1.0) 0.28 (0.11–1.11) 0.19 (0.07–0.47) 0.19 (0.10–0.85) 0.147
Note: Data expressed as medians and IQRs or n (%) when appropriate. Comparisons between continuous variables were done using a non-parametric test (Kruskal-
Wallis); associations between categorical variables were analyzed using the χ2 test; *p<0.05.
BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HDL, 
high density lipoprotein; iPTH, intact parathyroid hormone; LDL, low density lipoprotein; mCCI, modified Charlson Comorbidity Index; SBP, systolic blood pressure; 
TSAT, transferrin saturation; uPCr, urinary protein-to-creatinine ratio.
table 1 Continued 
Figure 1 Cumulative incidence rates for the competing 
endpoints of end-stage renal disease or death.
original research
far less likely to develop kidney failure than to die, espe-
cially from cardiovascular disease, even with higher CKD 
stage.6 7 15 16
However, our results differ from others, also from 
patients with CKD referred for nephrologist care,17 18 who 
have been showed to have either similar or even higher risk 
of ESRD compared with death. We can speculate about 
the reasons for these differences, namely our patients were 
older, with a higher burden of comorbidity and frailty. 
In fact, 25% of our patients have a severe mCCI score 
(CCI ≥5), 43% have some degree of functional dependency 
and 11% had a cognitive impairment.
Our cohort fits the frailty phenotype associated with 
CKD and geriatric syndrome,19 20 in contrast with other 
elderly CKD European cohorts newly referred to nephrol-
ogists,16 that despite older than our patients, had a good 
health status, reflecting a selection bias in referring patients 
for nephrology care, not found in our group.
To better understand the chances associated with the 
competing risks between mortality and ESRD, in elderly 
patients with CKD, where the supply of conservative 
management is weighed against the benefits and costs of 
RRT, we have applied a competing-risks model13 that looks 
at the cumulative incidence of ESRD or death before ESRD 
while also taking into consideration competing risk of the 
alternate outcome. We believe that such approach better 
identifies prognostic factors for a particular event in the 
presence of competing risks and provide an important tool 
for better decision-making.21
In the competing-risk framework, patients who are 
younger, with creatinine higher than 1.6 mg/dL, hemoglobin 
lower than 11 g/dL, had previous peripheral vascular disease 
and one or more hospitalizations during the follow-up, are 
more likely to reach ESRD. Those who are older, with 
creatinine higher than 1.6 mg/dL, hemoglobin lower than 
11 g/dL, mCCI score ≥5 and one or more hospitalizations 
during the follow-up, are more likely to die.
Our findings confirm that renal function at baseline was 
an important predictor for both ESRD and mortality6 22–25 
although this association was stronger for ESRD than for 
death, still reinforce the importance of early nephrology 
referral. In fact, in our cohort a shorter time between 
referral and ESRD was also associated with RRT initiation 
by catheter as primary access.
We found, as others,26 that anemia (hemoglobin <11 g/
dL) was a predictor of mortality and ESRD, undoubtedly 
related with adverse cardiovascular effects and the potential 
role of hypoxia on CKD progression, particularly important 
in this elderly population. This highlights the importance of 
anemia treatment although the target hemoglobin is still a 
matter of debate.14 27
The occurrence of one or more hospitalizations was 
common in our cohort and it was associated with both 
outcomes (ESRD and death). The increased risk for 
mortality among patients with hospitalization is consis-
tent with other studies, assuming that the majority of those 
hospitalizations were cardiovascular-related,28 29 or associ-
ated with an infection event, also known a risk factor for 
increased cardiovascular events and mortality in patients 
with CKD.30
The occurrence of hospitalizations events during the 
follow-up was also associated with ESRD. In our group the 
global and cardiovascular hospitalization rate was higher in 
patients with ESRD, than in the patients who died before 
RRT initiation. These findings are consistent with other 
studies,29 31 32 as cardiovascular admissions may have served 
as a marker for patients who had more progressive isch-
emic nephropathy, or more important, related to a superim-
posed acute kidney injury (AKI) episode on the underlying 
CKD.29 33 AKI episodes, frequent in elderly population, 
may accelerate progression of renal disease.34 35
We demonstrated that peripheral vascular disease was an 
independent predictor for ESRD, but was not associated 
with increased pre-ESRD mortality. These findings extend 
group.bmj.com on April 3, 2018 - Published by http://jim.bmj.com/Downloaded from 
1046 Santos J, et al. J Investig Med 2017;65:1041–1048. doi:10.1136/jim-2017-000480
table 2 Risk factors associated with death and ESRD (Cox regression analysis)
esrd death
csHr (95% cI) p Value csHr (95% cI) p Value
Baseline
Age, years 0.95 (0.91 to 1.00) 0.049 1.04 (1.01 to 1.07) 0.004
Creatinine (>1.6 vs <1.6 mg/dL) 3.64 (1.58 to 8.38) 0.002 2.27 (1.44 to 3.57) <0.001
Hb (<11.0 vs >11.0 g/dL) 2.72 (1.35 to 5.49) 0.005 2.20 (1.49 to 3.26) <0.001
CCI score
  (3–4 vs 1–2)
  (≥5 vs 1–2)
0.55 (0.22 to 1.39)
0.80 (0.33 to 1.96)
0.205
0.626
1.35 (0.80 to 2.29)
2.82 (1.70 to 4.67)
0.258
<0.001
Peripheral vascular disease
(yes vs no)
3.60 (1.70 to 7.60) 0.001 1.03 (0.64 to 1.68) 0.890
DM vs other CKD etiologies 1.75 (0.85 to 3.58) 0.127 1.02 (0.67 to 1.55) 0.930
During the follow-up
Hospitalizations (yes vs no) 1.72 (1.17 to 2.52) 0.006 1.84 (1.44 to 2.36) <0.001
Note: Values given as csHR (95% CI) for risk factors associated with ESRD and death prior to ESRD.
CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; csHR, cause-specific HR; DM, diabetes mellitus; ESRD, end-stage renal disease; Hb, hemoglobin.
table 3 Risk factors associated with death and ESRD (Fine and Gray model13)
esrd death
sHr (95% cI) p Value sHr (95% cI) p Value
Baseline
Age, years 0.94 (0.89 to 0.98) 0.009 1.06 (1.03 to 1.09) <0.001
Creatinine (>1.6 vs <1.6 mg/dL) 3.26 (1.40 to 7.60) 0.006 2.03 (1.25 to 3.29) 0.004
Peripheral vascular disease (yes vs no) 3.45 (1.68 to 7.10) 0.001 0.82 (0.49 to 1.34) 0.435
CCI score
  (3–4 vs 1–2)
  (≥5 vs 1–2)
0.57 (0.24 to 1.35)
0.54 (0.23 to 1.28)
0.202
0.164
1.53 (0.87 to 2.69)
3.01 (1.75 to 5.19)
0.137
<0.001
Hb (<11.0 vs >11.0 g/dL) 2.15 (1.09 to 4.24) 0.027 1.91 (1.25 to 2.92) 0.003
DM vs other CKD etiologies 1.72 (0.84 to 3.53) 0.139 0.84 (0.54 to 1.32) 0.447
During the follow-up
Hospitalizations (yes vs no) 1.56 (1.04 to 2.35) 0.031 1.73 (1.33 to 2.25) <0.001
Note: Values given as sHR (95% CI) for risk factors associated with ESRD and death prior to ESRD.
CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; DM, diabetes mellitus; ESRD, end-stage renal disease.; Hb, hemoglobin; sHR, subdistribution HR. 
original research
the association between vascular disease and CKD progres-
sion founded in other studies,31 36 37 given that peripheral 
vascular disease is the result of an atherosclerotic process 
similar to that one seen in cardiovascular disease. As we 
know, atherosclerosis is a potentially important mechanism 
of kidney disease in older persons38 39 and increases the 
susceptibility for AKI and CKD progression.40 A study in 
European cohort,41 also using a competing risks modeling 
approach, showed that the endogenous inhibitor of nitric 
oxide synthase, asymmetric dimethylarginine, considered 
one of the strongest markers of atherosclerosis, was an 
independent predictor of progression to dialysis and death 
in patients with CKD.
A reduced ankle–brachial index reflects peripheral 
arterial disease, and some studies demonstrated that this 
atherosclerotic disease marker predicted accelerated renal 
function decline, in general population,42 and also in peri-
toneal dialysis patients.43
Given that finding, our study suggests that the presence 
of peripheral arterial disease, although reflecting an athero-
sclerotic systemic process also involving the kidneys, may 
be a potential marker for renal function decline in patients 
with CKD, through other mechanisms, in addition to the 
traditional association of CKD with vascular damage.
The higher burden of CV risk factors, and prevalent 
vascular disease, present in our cohort, and the association 
between peripheral vascular disease and ESRD that we 
found, may partially explain the highest incidence of ESRD 
of Portuguese population among European countries,4 
because data from the PREVADIAB Study44 have shown 
that the prevalence of CKD stages 3–5 was 6.1%, which is 
similar to that in other Western countries. The reasons for 
this disparity are still a matter of debate. Although socio-
economic and political factors still play a part in RRT rates 
around the world, other important factors are genetics, 
birth weight, dietary habits, and diabetes prevalence. 
Another important issue is the age pattern at beginning of 
RRT. In countries with lower RRT incidence, the median 
age at start of RRT appears to be lower, suggesting that 
countries with higher RRT incidence, like Portugal, start 
older patients in RRT and this may contribute to differ-
ences in RRT epidemiology between countries.45 In this 
respect, there is an urgent need for concrete evidence on 
the relative benefit of conservative treatment versus RRT 
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in the elderly as well as on the optimal timing of RRT 
initiation.
Finally, we found that mCCI score ≥5 was an inde-
pendent predictor for pre-ESRD death, but not for RRT 
initiation. The CCI has been widely used and validated in 
patients with ESRD and seemed to be significantly more 
predictive for mortality than other comorbidity scoring 
systems46 47 This is evidenced by studies demonstrating 
that elderly patients with CKD are likely to have a higher 
burden of comorbidity and frailty, which are markers of 
worst survival.46
Old age alone should not be used as an absolute barrier 
to treatment when considering the benefits of dialysis 
in elderly patients with CKD.48 However, in the elderly 
patients with CKD with a high burden of comorbidity, 
conservative management may be a therapeutic option, as 
dialysis is unlikely to prolong or improve quality of life.49–51
Also, considering the likelihood of death prior to ESRD 
makes preparation for RRT, as the placement of an arterio-
venous access unnecessary and potentially harmful.52
The strengths of our study include the rigorous explo-
ration of the first Portuguese CKD cohort that included 
patients aged 65 years over, newly referred to nephrology, 
reflecting current clinical practice. We implemented a 
competing-risk framework for the statistical analysis to 
examine risk factors based on available clinical and labo-
ratory data, for ESRD and differentiating them from those 
that increase mortality, which is an important tool to guide 
clinical decision process.
The effect of peripheral vascular disease as an inde-
pendent predictor for ESRD in our cohort, although it 
deserves more research, reinforces the importance of stra-
tegic targeting vascular risk screening and reduction in this 
population.
There are certain limitations to our research. First, this 
is a single-center retrospective study. Second, due to the 
overall small number of patients who initiated RRT (n=36), 
it is not possible to identify the risk factors for progression 
within each CKD stage. In the stages 3 and 4, only 8 and 
11 patients progressed to dialysis, respectively. Thus, we do 
not have sufficient number of events for performing a reli-
able survival analysis using mortality as a competing event.
Third, defining ESRD as the RRT initiation has the 
disadvantage of being dependent on local clinical practice. 
Fourth, proteinuria could not be included in the multivari-
able models due to the percentage of missings and, there-
fore, we could not analyze the effect of proteinuria on the 
risk of ESRD or death. Finally, because this cohort only 
comprised patients attending nephrology outpatient clinic, 
which can introduce a bias of referral, the results may not 
be generalizable to a non-referred population.
conclusIon
In summary, we found that newly referred older patients 
with CKD are substantially more likely to die than to reach 
ESRD. By using a competing-risk approach based on avail-
able clinical and laboratory data, we could identify risk 
factors predictors of CKD progression and distinguishing 
them from those that increase mortality, which may allow 
us to use them as a decision-making tool to guide clinical 
decision process.
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